CA 125 Test Market Research Report - Forecast Till 2027

CA 125 Test Market Information: By Devices (Spectrometer, Analyzer, Sample Collection Tube, Otopic Labeled Peptides), Indication (Cancer, Uterine Fibroid, Endometriosis), End User (Hospitals & Clinics, Diagnostic Centers) - Forecast till 2027

ID: MRFR/LS/3526-HCR | February 2021 | Region: Global | 110 pages

CA 125 Test Market Overview


Cancer Antigen (CA) test is used to diagnose various disease such as cancer, uterine fibroids, endometriosis, and liver disease. CA 125 is a protein that is found in the blood. The test is mostly widely used of the diagnosis of ovarian cancer in women. Normal levels of CA 125 in the blood is less 30 units per ml. and elevated levels for CA 125 signals the presence cancer in the ovary. Besides diagnosis, the CA 125 test is also used for monitoring ovarian cancer, as well as for screening ovarian cancer in women suspected to be at high risk for developing the disease.


Increasing demand for cancer diagnosis and treatment services, rising prevalence of cancer among the women and increasing emphasis on women healthcare. Furthermore, extensive diagnostic tests for cancer, also fuel the CA 125 test market growth. The growth of the CA 125 test market is restrained by the high cost of devices used in cancer diagnostics.


According to the American Cancer Society, in 2015, ovarian cancer represents only 3% of all malignancies in the U.S. women. Also there is a rise in the death rate due to various types of cancer of reproductive tract in women. Additionally, in the U.S., 22,280 women were estimated to have received an ovarian cancer diagnostic services and 14,240 deaths.


The CA 125 test market is blooming and is expected to grow at a CAGR of 5.7% during the forecast period.


FIGURE 1: Global CA 125 test Market by Type, 2016 (%)
CA 125 Test Market
Source: World Health Organization, Centers for Disease Control and Prevention, European Society of Clinical Microbiology and Infectious Diseases, U.S. National Library of Medicine, National Organization for Rare Disorders, The International Society for Human and Animal Mycology, Expert Interview Market Research Future Analysis, Annual report, White paper, Company Presentation 


Intended Audience



  • Medical Device Manufacturers

  • Medical Device Suppliers

  • Medical Research Laboratories

  • Research and Development (R&D) Companies

  • Market Research and Consulting Service Providers

  • Potential Investors


Segments 


The CA 125 test market is segmented on the basis of devices and accessories, devices, and end user.


On the basis of devices and accessories, CA 125 test market is segmented into spectrometer, analyzer, sample collection tubes, isotopic labeled peptides, and others.


On the basis of indication, the CA 125 test market is segmented into cancer, uterine fibroids, endometriosis, liver diseases, and others. Cancer is further segmented into ovarian cancer, endometrial cancer, fallopian tube cancer, stomach cancer, breast cancer, and others.


On the basis of end user, the CA 125 test market is segmented into hospitals & clinics, diagnostic centers, and others.

Key Players in the Global CA 125 Test Market 


Some of the key players in CA 125 test market are Allergan plc. (U.K), Amgen Inc. (U.S.), Bayer (Germany), BD (U.S.), Eli Lilly Company (U.S.) , Merck & Co., Inc. (U.S.), Pfizer Inc. (U.S.), Teva Pharmaceuticals Private Limited (Israel), AMAG Pharmaceuticals (U.S.), Johnson & Johnson (U.S.), Sanofi (France), Novartis (Germany), AbbVie Inc. (U.S.), GlaxoSmithKline plc. (U.S.), and others.


Research Methodology


Global CA 125 Test Market
Source: World Health Organization, Centers for Disease Control and Prevention, European Society of Clinical Microbiology and Infectious Diseases, U.S. National Library of Medicine, National Organization for Rare Disorders, The American Autoimmune Related Diseases Association, The International Society for Human and Animal Mycology, Expert Interview Market Research Future Analysis, Annual report, White paper, Company Presentation


Regional Analysis of the CA 125 Test Market                


America holds the first position in the CA 125 test market owing to the rising prevalence of ovarian cancer in the U.S. and Canada. Additionally, the availability of a wide range of diagnosis and treatment methods for cancer and technological advancement in the field of oncology, also support the growth of the market in American countries. Presence of key player in the market also accelerates the growth of the CA 125 test market. These players are engaged in various strategic approaches such as mergers, acquisition, collaborations, partnership, and research activities, leading to the development of the market in North America.


In Europe, the market shows extensive growth owing to extensive research and development activities, and increasing demand for new medical devices for diagnosis of cancer drive the growth of the CA 125 test market. Germany, U.K, and France acquire first, second and third place respectively, in the European CA 125 test market.


The market in Asia Pacific is expected to grow at the fastest pace whose market is driven rising awareness about reproductive health and diseases among women, and improving healthcare infrastructure. Availability of highly qualified healthcare professionals such as physicians, surgeons and gynecologist in the developing regions such as India, Japan and China further fuel the CA 125 test market.


The Middle East & Africa also show a steady rise in the market owing to low prevalence of ovarian cancer, rising demand for diagnostic services and growing emphasis on diagnosis and treatment of cancer disease. Developing healthcare infrastructure in the Middle East also fuels the growth of the CA 125 test market. In the Middle East & Africa, the Middle East accounts for the largest market share owing to the availability of better healthcare services in the Middle East countries than in Africa.



Report Scope:
Report Attribute/Metric Details
  Market Size   2027: Significant Value
  CAGR   5.7% (2017-2023)
  Base Year   2019
  Forecast Period   2020-2027
  Historical Data   2018
  Forecast Units   Value (USD Million)
  Report Coverage   Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
  Segments Covered   Devices and Accessories, Devices, and End user
  Geographies Covered   North America, Europe, Asia-Pacific, and Rest of the World (RoW)
  Key Vendors   Allergan plc. (U.K), Amgen Inc. (U.S.), Bayer (Germany), BD (U.S.), Eli Lilly Company (U.S.) , Merck & Co., Inc. (U.S.), Pfizer Inc. (U.S.), Teva Pharmaceuticals Private Limited (Israel), AMAG Pharmaceuticals (U.S.), Johnson & Johnson (U.S.), Sanofi (France), Novartis (Germany), AbbVie Inc. (U.S.), GlaxoSmithKline plc. (U.S.), and others
  Key Market Opportunities   New product launches and R&D Amongst major key Players
  Key Market Drivers

  • Increasing demand for cancer diagnosis and treatment services
  • Rising prevalence of cancer
  • Increasing emphasis on women healthcare


  • Speak to Analyst Ask for Customization

    Frequently Asked Questions (FAQ) :


    CA 125 test market CAGR 5.7% during the forecast period.

    CA 125 test market would get boosted by growing demand for cancer diagnosis.

    The devices and accessories mentioned in the CA 125 test market are analyzer, spectrometer, isotopic labeled peptides, sample collection tubes, and others.

    CA 125 test market players are Bayer (Germany), Allergan plc. (U.K), Amgen Inc. (U.S.), Merck & Co., Inc. (U.S.), BD (U.S.), Eli Lilly Company (U.S.), Teva Pharmaceuticals Private Limited (Israel), Pfizer Inc. (U.S.), Johnson & Johnson (U.S.), Sanofi (France), AMAG Pharmaceuticals (U.S.), AbbVie Inc. (U.S.), GlaxoSmithKline plc. (U.S.), Novartis (Germany), and others.

    The Americas would take charge of the CA 125 test market.

    Table of Content

    1. Report Prologue

    2. Market Introduction

    2.1 Definition

    2.2 Scope of the Study

    2.2.1 Research Objective

    2.2.2 Assumptions

    2.2.3 Limitations

    3. Research Methodology

    3.1 Introduction

    3.2 Primary Research

    3.3 Secondary research

    3.4 Market Size Estimation

    4. Market Dynamics

    4.1 Drivers

    4.2 Restrains

    4.3 Opportunities

    4.4 Challenges

    4.5 Macroeconomic Indicators

    4.6 Technology Trends & Assessment

    5. Market Factor Analysis

    5.1 Porters Five Forces Analysis

    5.1.1 Bargaining Power of Suppliers

    5.1.2 Bargaining Power of Buyers

    5.1.3 Threat of New Entrants

    5.1.4 Threat of Substitutes

    5.1.5 Intensity of Rivalry

    5.2 Value Chain Analysis

    5.3 Investment Feasibility Analysis

    5.4 Pricing Analysis

    6. Global CA 125 test Market, by Device and Accessorie

    6.1 Introduction

    6.2 Spectrometer

    6.2.1 Market Estimates & Forecast, 2020-2027

    6.3 Analyzer

    6.3.1 Market Estimates & Forecast, 2020-2027

    6.4 Sample Collection Tubes

    6.4.1 Market Estimates & Forecast, 2020-2027

    6.5 Otopic Labeled Peptides

    6.5.1 Market Estimates & Forecast, 2020-2027

    6.6 Others

    6.6.1 Market Estimates & Forecast, 2020-2027

    7. Global CA 125 test Market, by Indication

    7.1 Introduction

    7.2 Cancer

    7.2.1 Market Estimates & Forecast, 2020-2027

    7.2.2 Ovarian cancer

    7.2.3 Endometrial cancer

    7.2.4 Fallopian tube cancer

    7.2.5 Stomach cancer

    7.2.6 Breast cancer

    7.2.7 Others

    7.3 Uterine fibroids

    7.3.1 Market Estimates & Forecast, 2020-2027

    7.4 Endometriosis

    7.4.1 Market Estimates & Forecast, 2020-2027

    7.5 Liver disease

    7.5.1 Market Estimates & Forecast, 2020-2027

    7.6 Others

    7.6.1 Market Estimates & Forecast, 2020-2027

    8. Global CA 125 test Market, by End User

    8.1 Introduction

    8.2 Hospitals & Clinics

    8.2.1 Market Estimates & Forecast, 2020-2027

    8.3 Diagnostic Centers

    8.3.1 Market Estimates & Forecast, 2020-2027

    9. Global CA 125 test Market, by Region

    9.1 Introduction

    9.2 Americas

    9.2.1 North America

    9.2.1.1 U.S.

    9.2.1.1 Canada

    9.2.2 South America

    9.3 Europe

    9.3.1 Western Europe

    9.3.1.1 Germany

    9.3.1.2 France

    9.3.1.3 U.K

    9.3.1.4 Italy

    9.3.1.5 Spain

    9.3.1.6 Rest of Western Europe

    9.3.2 Eastern Europe

    9.4 Asia Pacific

    9.4.1 Japan

    9.4.2 China

    9.4.3 India

    9.4.4 Australia

    9.4.5 Republic of Korea

    9.4.6 Rest of Asia Pacific

    9.5 The Middle East & Africa

    9.5.1 United Arab Emirates

    9.5.2 Saudi Arabia

    9.5.3 Oman

    9.5.4 Kuwait

    9.5.5 Qatar

    9.5.6 Rest of the Middle East & Africa

    10 Company Landscape

    10.1 Introduction

    10.2 Market Share Analysis

    10.3 Key Development & Strategies

    10.3.1 Key Developments

    11 Company Profiles

    11.1 Allergan plc.

    11.1.1 Company Overview

    11.1.2 Product Overview

    11.1.3 Financials

    11.1.4 SWOT Analysis

    11.2 Bayer

    11.2.1 Company Overview

    11.2.2 Product Overview

    11.2.3 Financial Overview

    11.2.4 Key Developments

    11.2.5 SWOT Analysis

    11.3 BD

    11.3.1 Company Overview

    11.3.2 Product Overview

    11.3.3 Financial Overview

    11.3.4 Key Development

    11.3.5 SWOT Analysis

    11.4 Eli Lilly Company

    11.4.1 Company Overview

    11.4.2 Product/Business Segment Overview

    11.4.3 Financial Overview

    11.4.4 Key Development

    11.4.5 SWOT Analysis

    11.5 Merck & Co., Inc.

    11.5.1 Company Overview

    11.5.2 Product Overview

    11.5.3 Financial overview

    11.5.4 Key Developments

    11.6 Pfizer Inc.

    11.6.1 Overview

    11.6.2 Product Overview

    11.6.3 Financials

    11.6.4 Key Developments

    11.6.5 SWOT Analysis

    11.7 Others

    12 MRFR Conclusion

    12.1 Key Findings

    12.1.1 From CEO’s View Point

    12.1.2 Unmet Needs of the Market

    12.2 Key Companies to Watch

    12.3 Prediction of Oncology Industry

    13 Appendix

    LIST OF TABLES

    Table 1 CA 125 test Industry Synopsis, 2020-2027

    Table 2 Global CA 125 test Market Estimates and Forecast, 2020-2027, (USD Million)

    Table 3 Global CA 125 test Market by Region, 2020-2027, (USD Million)

    Table 4 Global CA 125 test Market by Devices and Accessories, 2020-2027, (USD Million)

    Table 5 Global CA 125 test Market by Indication, 2020-2027, (USD Million)

    Table 6 Global CA 125 test Market by End Users, 2020-2027, (USD Million)

    Table 7 North America CA 125 test Market by Devices and Accessories, 2020-2027, (USD Million)

    Table 8 North America CA 125 test Market by Indication, 2020-2027, (USD Million)

    Table 9 North America CA 125 test Market by End Users, 2020-2027, (USD Million)

    Table 10 US CA 125 test Market by Devices and Accessories, 2020-2027, (USD Million)

    Table 11 US CA 125 test Market by Indication, 2020-2027, (USD Million)

    Table 12 US CA 125 test Market by End Users, 2020-2027, (USD Million)

    Table 13 Canada CA 125 test Market by Devices and Accessories, 2020-2027, (USD Million)

    Table 14 Canada CA 125 test Market by Indication, 2020-2027, (USD Million)

    Table 15 Canada CA 125 test Market by End Users, 2020-2027, (USD Million)

    Table 16 South America CA 125 test Market by Devices and Accessories, 2020-2027, (USD Million)

    Table 17 South America CA 125 test Market by Indication, 2020-2027, (USD Million)

    Table 18 South America CA 125 test Market by End Users, 2020-2027, (USD Million)

    Table 19 Europe CA 125 test Market by Devices and Accessories, 2020-2027, (USD Million)

    Table 20 Europe CA 125 test Market by Indication, 2020-2027, (USD Million)

    Table 21 Europe CA 125 test Market by End Users, 2020-2027, (USD Million)

    Table 22 Western Europe CA 125 test Market by Devices and Accessories, 2020-2027, (USD Million)

    Table 23 Western Europe CA 125 test Market by Indication, 2020-2027, (USD Million)

    Table 24 Western Europe CA 125 test Market by End Users, 2020-2027, (USD Million)

    Table 25 Eastern Europe CA 125 test Market by Devices and Accessories, 2020-2027, (USD Million)

    Table 26 Eastern Europe CA 125 test Market by Indication, 2020-2027, (USD Million)

    Table 27 Eastern Europe CA 125 test Market by End Users, 2020-2027, (USD Million)

    Table 28 Asia Pacific CA 125 test Market by Devices and Accessories, 2020-2027, (USD Million)

    Table 29 Asia Pacific CA 125 test Market by Indication, 2020-2027, (USD Million)

    Table 30 Asia Pacific CA 125 test Market by End Users, 2020-2027, (USD Million)

    Table 31 Middle East & Africa CA 125 test Market by Devices and Accessories, 2020-2027, (USD Million)

    Table 32 Middle East & Africa CA 125 test Market by Indication, 2020-2027, (USD Million)

    Table 33 Middle East & Africa CA 125 test Market by End Users, 2020-2027, (USD Million)

    LIST OF FIGURES

    Figure 1 Research Process

    Figure 2 Segmentation for Global CA 125 test Market

    Figure 3 Segmentation Market Dynamics for CA 125 test Market

    Figure 4 Global CA 125 test Market Share, by Devices and Accessories, 2020

    Figure 5 Global CA 125 test Market Share, by Indication, 2020

    Figure 6 Global CA 125 test Market Share, by End Users, 2020

    Figure 7 Global CA 125 test Market Share, by Region, 2020

    Figure 8 North America CA 125 test Market Share, by Country, 2020

    Figure 9 Europe CA 125 test Market Share, by Country, 2020

    Figure 10 Asia Pacific CA 125 test Market Share, by Country, 2020

    Figure 11 Middle East & Africa CA 125 test Market Share, by Country, 2020

    Figure 12 Global CA 125 test Market: Company Share Analysis, 2020 (%)

    Figure 13 Allergan plc.: Key Financials

    Figure 14 Allergan plc.: Segmental Revenue

    Figure 16 Allergan plc: Geographical Revenue

    Figure 17 Bayer: Key Financials

    Figure 18 Bayer: Segmental Revenue

    Figure 19 Bayer: Geographical Revenue

    Figure 20 BD: Key Financials

    Figure 21 BD: Segmental Revenue

    Figure 22 BD: Geographical Revenue

    Figure 23 Eli Lilly Company: Key Financials

    Figure 24 Eli Lilly Company: Segmental Revenue

    Figure 25 Eli Lilly Company: Geographical Revenue

    Figure 26 Cynosure, Inc.: Key Financials

    Figure 27 Cynosure, Inc.: Segmental Revenue

    Figure 28 Cynosure, Inc.: Geographical Revenue

    Figure 29 Merck & Co., Inc. : Key Financials

    Figure 30 Merck & Co., Inc. : Segmental Revenue

    Figure 31 Merck & Co., Inc. : Geographical Revenue

    Figure 32 Pfizer Inc.: Key Financials

    Figure 33 Pfizer Inc.: Segmental Revenue

    Figure 34 Pfizer Inc.: Geographical Revenue